Page last updated: 2024-11-05

dimethylacetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dimethylacetamide (DMAc) is a colorless liquid with a slight amine odor. It is a highly polar aprotic solvent that is widely used in various industrial and laboratory applications. DMAc is typically synthesized by reacting acetic acid with dimethylamine. It is known for its high boiling point, good solvency properties, and ability to dissolve a wide range of organic and inorganic compounds. DMAc is often employed as a solvent in various processes, including polymer production, fiber spinning, and pharmaceutical manufacturing. Its use in these applications is driven by its ability to dissolve and facilitate reactions involving polymers, resins, and other materials. It is also used as a reaction medium for various chemical reactions, including nucleophilic substitutions and eliminations. DMAc is an important industrial chemical with a range of applications, but it is also a potential health hazard. Exposure to DMAc can cause irritation to the skin, eyes, and respiratory system. Inhalation or ingestion can be harmful. Studies on DMAc often focus on its environmental impact, its potential health risks, and its use in developing safer alternatives. DMAc is an important solvent in several industrial and scientific applications, but its use is balanced against its potential health and environmental risks. Continued research aims to develop safer alternatives and optimize its usage to minimize negative impacts.'

hallucinogen : Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations and other alterations of mood and thinking. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

N,N-dimethylacetamide : A member of the class of acetamides that is acetamide in which the hydrogens attached to the N atom have been replaced by two methyl groups respectively. Metabolite observed in cancer metabolism. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID31374
CHEMBL ID11873
CHEBI ID84254
MeSH IDM0062145

Synonyms (126)

Synonym
hallucinogen
sk 7176
nsc-3138
acetic acid, dimethylamide
acetdimethylamide
dimethylacetamide
127-19-5
u-5954
n,n-dimethylethanamide
dimethylamide acetate
nsc 3138
dimethylacetone amide
wln: 1vn1 & 1
cbc 510337
nsc3138
n,n-dimethylacetamide
dmac
acetic acid,amide,n,n-dimethyl
acetamide, n,n-dimethyl-
inchi=1/c4h9no/c1-4(6)5(2)3/h1-3h
n.n-dimethylacetamide
dimethyl acetamide
ai3-15276
acetyldimethylamine
einecs 204-826-4
dimethylamid kyseliny octove [czech]
hsdb 74
ccris 4623
NCGC00159401-02
n,n-dimethylacetamide, for peptide synthesis, >=99.8% (gc)
n,n-dimethylacetamide, anhydrous, 99.8%
n-acetyldimethylamine
D0641
AKOS000118789
CHEMBL11873
n,n-dimethyl-acetamide
chebi:84254 ,
NCGC00159401-03
dimethylacetamid
ec 204-826-4
dimethylamid kyseliny octove
jcv5vdb3hy ,
unii-jcv5vdb3hy
NCGC00256375-01
tox21_302787
dtxsid5020499 ,
dtxcid90499
cas-127-19-5
tox21_202174
NCGC00259723-01
C20339
n,n-dimethyl acetamide
n,n-dimethylacetoamide
FT-0642826
FT-0629514
n,n-dimethylacetamide [mi]
n,n-dimethylacetamide [usp-rs]
dimethylacetamide [mart.]
dimethylacetamide [ep monograph]
n,n-dimethylacetamide [ii]
n,n-dimethylacetamide [hsdb]
n,n-dimethylacetamide [vandf]
n, n-dimethylacetoamide
dimethylacteamide
dimethyacetamide
n,n-dimethylacet-amide
n,n-dimethylactamide
n,n -dimethylacetamide
n,n-di-methylacetamide
n,n-dimethyl- acetamide
dimethyl-acetamide
dimethylactamide
n,n-dimethyl acetoamide
trimethylformamide
n,-n-dimethylacetamide
n,n,-dimethyl-acetamide
n, n-dimethylacetamide
dimeihyl acetamide
n,n,-dimethylacetamide
n,n dimethylacetamide
n,n-dimethyacetamide
n,n-dimethylacetamide, anhydrous
acetyl dimethylamine
ch3con(ch3)2
acetic acid dimethylamide
5y9 ,
W-108388
mfcd00008686
STL482892
n,n-dimethylacetamide, hplc grade
n,n-dimethylacetamide, analytical standard
F0001-0392
n,n-dimethylacetamide, reagentplus(r), >=99%
n,n-dimethylacetamide, saj special grade
n,n-dimethylacetamide, spectrophotometric grade, >=99%
n,n-dimethylacetamide, saj first grade, >=99.0%
n,n-dimethylacetamide, puriss. p.a., >=99.5% (gc)
n,n-dimethylacetamide, for hplc, >=99.9%
n,n-dimethylacetamide, >=99%
n,n-dimethylacetamide, reagentplus(r), 99%
n,n-dimethylacetamide, anhydrous, zero2(tm), 99.8%
n, n-dimethylacetamide, ep
n,n-dimethylacetamide, for hplc, >=99.7%
n,n-dimethylacetamide, ar, >=99.5%
n,n-dimethylacetamide, vetec(tm) reagent grade, 98%
n,n-dimethylacetamide, uv hplc spectroscopic, 99%
n,n-dimethylacetamide, p.a., 99.5%
dimethylacetamide; n,n-dimethylacetamide
acetic acid-dimethylamide
acetamide-2,2,2-d3, n,n-di(methyl-d3)-
HY-W042416
CS-W023195
Q411452
residual solvent class 2 - n,n-dimethylacetamide
acetic acid-dimethylamide 1000 microg/ml in acetonitrile
n-dimethylacetamide
nsc820333
nsc-820333
acetamide, n,n-dimethyl-, labeled with deuterium (9ci)
BP-31151
n,n-dimethylacetamide, anhydrous, water < 50ppm
dimethylacetamide (mart.)
n,n-dimethylacetamide (usp-rs)
dimethylacetamide (ep monograph)
n-n-dimethylacetamide
n,n-dimethylacetamide (ii)

Research Excerpts

Overview

N,N-Dimethylacetamide (DMAc) is a widely used organic solvent in modern chemical industry with low to moderate hepatotoxicity to occupational health of employees. Dimethylacetamine is a skin-penetrating solvent able to induce hepatic damage after chronic exposure.

ExcerptReferenceRelevance
"N, N-Dimethylacetamide is an FDA approved solvent widely used in pharmaceutical industry to facilitate the solubility of lipophilic, high molecular weight drugs with poor water solubility. "( N, N-Dimethylacetamide, an FDA approved excipient, acts post-meiotically to impair spermatogenesis and cause infertility in rats.
Atanassova, N; Ghayor, C; Khera, N; Lindholm, AK; Pavlova, E; Weber, FE, 2020
)
1.59
"N,N-Dimethylacetamide (DMAc) is a widely used organic solvent in modern chemical industry with low to moderate hepatotoxicity to occupational health of employees. "( Dimethylacetamide-induced Hepatic Injury in Vitro: Mechanism and Potential Preventive Strategy.
Gong, W; Liu, X; Xu, YQ; Zhu, BL, 2016
)
2.44
"N,N-Dimethylacetamide (DMA) is a water-miscible solvent, FDA approved as excipient and therefore widely used as drug-delivery vehicle. "( N,N Dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment.
Caflisch, A; Dong, J; Ghayor, C; Gjoksi, B; Siegenthaler, B; Weber, FE, 2017
)
1.57
"Dimethylacetamide (DMAc) is a skin-penetrating solvent able to induce hepatic damage after chronic exposure. "( Toxicokinetics of dimethylacetamide (DMAc) in rat isolated perfused liver.
Borm, PJ; Evelo, CT; Henderson, PT; Palmen, NG, 1993
)
2.06
"Dimethylacetamide (DMAC) is a widely used industrial solvent. "( Developmental toxicity of dimethylacetamide by inhalation in the rat.
Ferenz, RL; Kennedy, GL; Solomon, HM; Staples, RE, 1991
)
2.02

Effects

ExcerptReferenceRelevance
"N,N-Dimethylacetamide (DMA) has a higher Gutmann donor number (DN) than that of H"( Achieving Highly Reversible Zinc Anodes via N, N-Dimethylacetamide Enabled Zn-Ion Solvation Regulation.
Cao, X; Chen, Y; Feng, Y; Liu, W; Shi, W; Wu, F; Xu, X; Yin, R; Zheng, D, 2022
)
1.46
"N,N-Dimethylacetamide (DMA) has a higher Gutmann donor number (DN) than that of H"( Achieving Highly Reversible Zinc Anodes via N, N-Dimethylacetamide Enabled Zn-Ion Solvation Regulation.
Cao, X; Chen, Y; Feng, Y; Liu, W; Shi, W; Wu, F; Xu, X; Yin, R; Zheng, D, 2022
)
1.46

Toxicity

ExcerptReferenceRelevance
" DMAC was not demonstrated to produce malformations in the rat fetus even at a level that was toxic to the dam."( Developmental toxicity of dimethylacetamide by inhalation in the rat.
Ferenz, RL; Kennedy, GL; Solomon, HM; Staples, RE, 1991
)
0.58
" DMAC was slightly more toxic with all treated rabbits dying of acute hepatic necrosis."( Acute and subchronic toxicity of dimethylformamide and dimethylacetamide following various routes of administration.
Kennedy, GL; Sherman, H, 1986
)
0.52
" There were no compound-related adverse effects on the incidence of clinical signs of toxicity in rats or mice."( Chronic toxicity/oncogenicity of dimethylacetamide in rats and mice following inhalation exposure.
Elliott, GS; Kennedy, GL; Makovec, GT; Malley, LA; Slone, TW, 1995
)
0.57
" OBJECTİVE: To investigate the toxic effects of different cryoprotectants and osmotic stress on Awassi ram sperm and to determine the relationship between oxidative and antioxidative status of the sperm."( Relationship between toxicity of cryoprotectants, osmotic and oxidative stresses in awassi ram sperm.
Aydilek, N; Bozkaya, F; Taskin, A; Varisli, O,
)
0.13
"Cryoprotectants without other additives have limited protection and glycerol can be toxic to spermatozoa."( Relationship between toxicity of cryoprotectants, osmotic and oxidative stresses in awassi ram sperm.
Aydilek, N; Bozkaya, F; Taskin, A; Varisli, O,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" Area under the plasma concentration curve (AUC) values were determined for DMAC and its metabolite N-methylacetamide (NMAC), following 6-h exposures (single exposure or last in a series of 10 exposures)."( Dimethylacetamide pharmacokinetics following inhalation exposures to rats and mice.
Hundley, SG; Kennedy, GL; Lieder, PH; McCooey, KT; Valentine, R, 1994
)
1.73
" Bu was used as reference solution, the pharmacokinetic analysis indicated an average bioavailability of oral high-dose Bu of 69%, ranging from <10% to virtually 100%."( Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.
Andersson, BS; Blume, KG; Champlin, RE; Chow, DS; Hu, WW; Madden, T; Tran, HT; Vaughan, WP, 2000
)
0.31
"It has become increasingly popular in drug development to conduct discovery pharmacokinetic (PK) studies in order to evaluate important PK parameters of new chemical entities (NCEs) early in the discovery process."( Post-column infusion study of the 'dosing vehicle effect' in the liquid chromatography/tandem mass spectrometric analysis of discovery pharmacokinetic samples.
Naidong, W; Shou, WZ, 2003
)
0.32
" The population pharmacokinetic analysis revealed a clearance of 86."( Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan.
Boos, J; Gruhn, B; Hempel, G; Klingebiel, T; Lanvers-Kaminsky, C; Oechtering, D; Vormoor, J, 2007
)
0.69
" Modern high-throughput small molecule drug discovery requires rapid screening of the pharmacokinetic parameters of multiple candidate molecules in parallel."( Solvent-based formulations for intravenous mouse pharmacokinetic studies: tolerability and recommended solvent dose limits.
Bowman, T; Dean, B; Messick, K; Sambrone, A; Schweiger, M; Thackaberry, EA; Valle, N; Wang, X; Xie, M, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
"The unpredictable intestinal absorption and erratic bioavailability of oral busulfan (Bu) has limited the drug's use in high-dose pretransplantation conditioning therapy."( Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.
Andersson, BS; Blume, KG; Champlin, RE; Chow, DS; Hu, WW; Madden, T; Tran, HT; Vaughan, WP, 2000
)
0.31
" The bioavailability of the formulation was tested on 4 female BALB/c mice."( Oral formulation of a novel antiviral agent, PG301029, in a mixture of gelucire 44/14 and DMA (2:1, wt/wt).
He, Y; Johnson, JL; Yalkowsky, SH, 2005
)
0.33
" Indeed, high protein concentrations are often required to achieve acceptable bioavailability and efficacy for many indications."( Polar solvents decrease the viscosity of high concentration IgG1 solutions through hydrophobic solvation and interaction: formulation and biocompatibility considerations.
Danilenko, DM; Gokarn, YR; Kamerzell, TJ; Li, M; McDowell, M; Pace, AL; Wang, YJ, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" At 282 ppm, both maternal weight gain during the exposure period and fetal weight were significantly decreased and accompanied by a significant dose-response trend."( Developmental toxicity of dimethylacetamide by inhalation in the rat.
Ferenz, RL; Kennedy, GL; Solomon, HM; Staples, RE, 1991
)
0.58
" No teratogenic effect of DMAC treatment was observed at or below dosage levels of 160 mg/kg/day."( Teratogenic response of dimethylacetamide in rats.
Johannsen, FR; Levinskas, GJ; Schardein, JL, 1987
)
0.58
" The extent of differentiation was dosage dependent, but the maximal dose of DMA was limited by toxicity mainly to the liver and lymphoid tissues."( Differentiation of murine embryonal carcinoma in vitro and in vivo with N,N-dimethyl acetamide.
Franquemont, D; Meng, X; Speers, WC, 1995
)
0.29
" Fifty percent effective doses (ED50) to block propagated compound action potentials (AP's) were obtained by examining dose-response relations for each solute."( An analysis of dimethylsulfoxide-induced action potential block: a comparative study of DMSO and other aliphatic water soluble solutes.
Gasser, K; Hahin, R; Larsen, J, 1996
)
0.29
" In these studies, dosing vehicles are typically employed in high concentrations to dissolve the test compounds in dose formulations."( Post-column infusion study of the 'dosing vehicle effect' in the liquid chromatography/tandem mass spectrometric analysis of discovery pharmacokinetic samples.
Naidong, W; Shou, WZ, 2003
)
0.32
" The energy supplied by these processing steps tends to overcome the energy barriers between different solid-state forms, thus yielding undesirable changes in the physicochemical and material characteristics of drugs or their dosage forms."( Effect of processing on Celecoxib and its solvates.
Bansal, AK; Chawla, G, 2004
)
0.32
" Male Sprague Dawley rats (N = 4 per group; approximately 200 g) were cannulated via the left jugular and dosed intravenously (IV) with the rapamycin control and micelle formulations (10 mg/kg, 1:9 ratio for rapamycin to PEG-b-PCL)."( Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin.
Davies, NM; Forrest, ML; Kwon, GS; Ohgami, Y; Yáñez, JA, 2008
)
0.35
" The in-vivo mouse micronucleus test was undertaken in wild-type C57Bl6J male mice dosed orally with SR-51for 14 days with a single daily dose up to 360 mg/kg/day (the maximum-tolerated dose)."( Genotoxicity studies of a desealant solvent mixture, SR-51.
Moscova, M; Narup, E; Oakes, DJ; Picker, K; Ritchie, HE; Webster, WS; Woodman, PD, 2009
)
0.35
"Low-volume protein dosage forms for subcutaneous injection pose unique challenges to the pharmaceutical scientist."( Polar solvents decrease the viscosity of high concentration IgG1 solutions through hydrophobic solvation and interaction: formulation and biocompatibility considerations.
Danilenko, DM; Gokarn, YR; Kamerzell, TJ; Li, M; McDowell, M; Pace, AL; Wang, YJ, 2013
)
0.39
" Assuming an increase in clearance overtime as found in our previous investigation, separate time factors for the two different dosing schedules included in the dataset were tested."( Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration.
Bartelink, IH; Boelens, JJ; Boos, J; Hempel, G; Trame, MN, 2013
)
0.68
" The rapid clearance with different dosing in patients of different body weights indicates that it is safe to use DMA in children in both a once and four times daily regimen."( Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration.
Bartelink, IH; Boelens, JJ; Boos, J; Hempel, G; Trame, MN, 2013
)
0.68
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
succinate to cytochrome bo oxidase electron transfer831
NADH to cytochrome bo oxidase electron transfer II526
D-lactate to cytochrome bo oxidase electron transfer527
glycerol-3-phosphate to cytochrome bo oxidase electron transfer529
proline to cytochrome bo oxidase electron transfer531
NADH to cytochrome bo oxidase electron transfer I1734
pyruvate to cytochrome bo oxidase electron transfer535

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency31.49960.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency55.48150.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency11.13660.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency18.74760.001530.607315,848.9004AID1224841; AID1224849
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency68.58960.000323.4451159.6830AID743066
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency67.21740.000627.21521,122.0200AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID28486Second-order rate constant (M-1 s-1) for the alkaline hydrolysis in water at 30 degrees C2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Acylating agents as enzyme inhibitors and understanding their reactivity for drug design.
AID70689Cell growth was measured on day 3, after murine erythroleukemia cells were exposed at a cell concentration of 1*10e5 cells/mL.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID70690Cell growth was measured on day 6 after murine erythroleukemia cells were exposed at a cell concentration of 1*10e5 cells/mL.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID70691Concentration producing the maximum percentage of benzidine-positive cells after 6-days of continuous exposure in murine leukemia cells.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID70688Percentage of benzidine-positive murine erythroleukemia cells on day 6.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (304)

TimeframeStudies, This Drug (%)All Drugs %
pre-199050 (16.45)18.7374
1990's28 (9.21)18.2507
2000's82 (26.97)29.6817
2010's124 (40.79)24.3611
2020's20 (6.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.46 (24.57)
Research Supply Index5.77 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index109.21 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.63%)5.53%
Reviews10 (3.13%)6.00%
Case Studies3 (0.94%)4.05%
Observational0 (0.00%)0.25%
Other304 (95.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]